Intradermal injection of lymphocytes in recurrent pregnancy loss patients

Phase 1

Recruiting

Conditions: Recurrent Pregnancy Loss(RPL).

Registration Number: IRCT20160422027520N19

Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 200

Inclusion Criteria

Having at least three consecutive abortions
Having regular menstrual cycles
BMI of people below 30
Have no uterine pathology
Our patients will be selected only from Azerbaijan.
Patients were selected whose semen analysis and DNA fragmentation test were normal.

Exclusion Criteria

Patients under the age of 18 and over 40 years
Patients who themselves or their spouse have abnormal karyotypes or genetic or chromosomal abnormalities.
Patients with chronic underlying disease who have to take certain medications.
Patients with intrauterine anomalies.
Having polycystic ovary syndrome
Patients who test positive for HIV, HCV or HBV

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Frequency of Treg and Th17 cells. Timepoint: Before and after the intervention. Method of measurement: Flow cytometry.;Gene expression levels of Foxp3 and RORyt. Timepoint: Before and after the intervention. Method of measurement: Real-time PCR.;Protein expression levels of Foxp3 and RORyt. Timepoint: Before and after the intervention. Method of measurement: Western blot.;Gene expression levels of IL-10, IL-17, IL-21, IL-23, TGF-ß. Timepoint: Before and after the intervention. Method of measurement: Real-time PCR.;Secretion levels of IL-10, IL-17, IL-21, IL-23, TGF-ß. Timepoint: Before and after the intervention. Method of measurement: ELISA.;Gene expression levels of mir-146a ? mir-155 ? mir-326. Timepoint: Before and after the intervention. Method of measurement: real-time PCR.

Secondary Outcome Measures